Final ProgramCPSA 2012
Transforming Drug Discovery & Development Through Innovation:
Past, Present and Future
October 1 - 4, 2012
Sheraton Bucks County Hotel
Langhorne, PA
Tuesday Evening
Session Synopsis
Dried Blood Spot Summit
Sponsored by Drummond Scientific and McKinley Scientific
Discussion Leaders: Qin Ji, Bristol-Myers Squibb and Olga Kavetskaia, Abbott Labs
Recently, there have been renewed interest by scientific community in using dried blood spot as a micro-sampling technology in drug development. Clear benefits and advantages of using this sampling technique drive research efforts and \continuing exploration of the possible solutions to managing and overcoming real and perceived limitations of this technology. While many organizations are still at the evaluation phase, some pioneers have implemented this technology in real studies. The DBS summit at CPSA 2012 will feature three introductory presentations followed by the interactive discussions with the panelists from multiple R&D organizations which are at the various stages of evaluation and implementations of DBS technology. We hope this evening session will further stimulate scientific dialog and sharing of real life successful experience with DBS technology. We are inviting you to join this interactive session and learn how DBS can provide best value to drug development and what scientific community is doing to advance this technology and build the foundation for its wide acceptance.
IQ/FDA Interactions
Chris Evans, GlaxoSmithKline
Challenges and Solutions
Leimin "Perry" Fan, Abbott Labs
DBS Clinical Studies
Shane Needham, Alturas Analytics
Panel Discussion
David Boulton, Bristol-Myers Squibb
Peter Bryan, Celgene
Donald Chace, Pediatrix Analytical
Chris Evans, GlaxoSmithKline
Leimin (Perry) Fan, Abbott Labs
Jim Kenney, Drummond Scientific
Wenkui Li, Novartis
Shane Needham, Alturas Analytics
Patricia Zane, Sanofi-Aventis
Return to program